Recent advances in research and care of familial hypercholesterolaemia Heterozygous familial hypercholesterolaemia is a common, autosomal semi-dominant condition characterised by elevation of LDL cholesterol from birth and early onset of atherosclerotic cardiovascular di...

Despite advances, #familial #hypercholesterolaemia is still inadequately diagnosed and undertreated, with many affected people remaining at high risk of early #cardiovascular disease www.thelancet.com/journals/lan...
#HeFH #HoFH #ASCVD

#MedSky #EndoSKY #CardioSky

Recent advances in research and care of familial hypercholesterolaemia Heterozygous familial hypercholesterolaemia is a common, autosomal semi-dominant condition characterised by elevation of LDL cholesterol from birth and early onset of atherosclerotic cardiovascular di...

With major advances in knowledge about the disease, #familial #hypercholesterolaemia has become an exemplar for the practice of precision and personalised medicine thelancet.com/journals/lan...
#HoFH #HeFH #ASCVD

#MedSky #EndoSky #CardioSky

Efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolaemia (ORION-16): a two-part, randomised, multicentre clinical trial In adolescents with HeFH, inclisiran was effective in lowering LDL cholesterol, with sustained efficacy over 2 years, and was well tolerated. These results support inclisiran as a potentially useful a...

The siRNA therapeutic inclisiran, on top of standard-of-care treatment, results in sustained lowering of LDL cholesterol in this paediatric patient population, with a favourable safety & tolerability profile that is consistent with studies in adult populations tinyurl.com/3hn8243k
#HeFH
#CardioSky

The siRNA therapeutic inclisiran, on top of standard-of-care treatment, results in sustained lowering of LDL cholesterol in this paediatric patient population, with a favourable safety & tolerability profile that is consistent with studies in adult populations www.thelancet.com/journals/lan...
#HeFH

Inclisiran for children: is it worth it? Familial hypercholesterolaemia is one of the most common inherited metabolic disorders, with heterozygous familial hypercholesterolaemia (HeFH) affecting more than 30 million individuals worldwide, a ...

Lluís Masana & Daiana Ibarretxe comment on:
Inclisiran for children: is it worth it? thelancet.com/journals/lan...
#heterozygous #familial #hypercholesterolaemia #HeFH #ASCVD

#MedSky #EndoSky #CardioSky

Efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolaemia (ORION-16): a two-part, randomised, multicentre clinical trial In adolescents with HeFH, inclisiran was effective in lowering LDL cholesterol, with sustained efficacy over 2 years, and was well tolerated. These results support inclisiran as a potentially useful a...

In this adolescent patient population with #HeFH and elevated #LDL #cholesterol despite standard of care, inclisiran was effective in lowering LDL cholesterol, showing sustained efficacy over 2 years of treatment, with a reduction of −33·7% from baseline at day 720 www.thelancet.com/journals/lan....

The application of implementation science to expanding knowledge of #familial #hypercholesterolaemia has enabled the development and design of potentially more effective models of care thelancet.com/journals/lan...
#HoFH #HeFH #ASCVD

#MedSky #EndoSky #CardioSky

Despite advances, #familial #hypercholesterolaemia remains an underdiagnosed and untreated condition, with an urgent need for the design and implementation of effective models of care www.thelancet.com/journals/lan...
#ASCVD #HeFH #HoFH

#MedSky #EndoSky #CardioSky

Recent advances in research and care of familial hypercholesterolaemia Heterozygous familial hypercholesterolaemia is a common, autosomal semi-dominant condition characterised by elevation of LDL cholesterol from birth and early onset of atherosclerotic cardiovascular di...

Heterozygous familial #hypercholesterolaemia is a common, autosomal semi-dominant condition characterised by elevation of #LDL #cholesterol from birth and early onset of #atherosclerotic #cardiovascular disease www.thelancet.com/journals/lan...
#HeFH #ASCVD

#MedSky #EndoSky #CardioSky

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Fami... -- Achieved primary endpoint of LS mean reduction vs placebo in LDL-C on top of maximally tolerated lipid modifying therapies at day 84 with statistically significant reduction (p0.0001) -- -- 21% obs...

Heterozygous familial hypercholesterolemia ( #HeFH)

phase 3 trial, lowered #LDL-c by another 33%?

10 mg obicetrapib
#cvprev #cardiosky #lipids #lipidology

ir.newamsterdampharma.com/news-release...

Congratulations to @newamsterdampharma.bsky.social

Another therapy for #HeFH
#cardioSky